26 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
27 Sep 22
Entry into a Material Definitive Agreement
8:08am
of cancer death in women in China and globally. An estimated 110,000 new cases of cervical cancer occur annually in China1. Treatment options are limited
8-K
EX-99.1
d73q8
6 Jan 22
Zai Lab Announces NDA Acceptance of
7:44am
8-K
EX-99.1
fvt1tyar62kh76t c7
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
DEF 14A
m50 3xqhvcsk9qu9bh
30 Apr 21
Definitive proxy
4:02pm
424B5
td49i6yynjxwikchl
21 Apr 21
Prospectus supplement for primary offering
4:45pm
424B5
9v1ez zxv8ydr
19 Apr 21
Prospectus supplement for primary offering
4:57pm
PRE 14A
wa417m5 zis
14 Apr 21
Preliminary proxy
4:00pm
10-K
07083bj v2cqs
1 Mar 21
Annual report
12:00am
6-K
EX-99.1
q90bng
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
8zc28bt bwy2
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
gxue6
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
yh7c7 1x8
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
424B2
trpwikyj
24 Jan 20
Prospectus for primary offering
7:24am
424B5
8yp3 3e0gmd
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
patcs
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am